Biomarkers such as tumor mutation burden and PD‐L1 protein expression lack accuracy for the identification of SCLC patients who will optimally benefit from atezolizumab plus carboplatin and etoposide combination chemotherapy.19 Here, CD274 is linked to neoplasm.